PT - JOURNAL ARTICLE AU - Ryan S. McGee AU - Julian R. Homburger AU - Hannah E. Williams AU - Carl T. Bergstrom AU - Alicia Y. Zhou TI - Model-driven mitigation measures for reopening schools during the COVID-19 pandemic AID - 10.1101/2021.01.22.21250282 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.22.21250282 4099 - http://medrxiv.org/content/early/2021/05/15/2021.01.22.21250282.short 4100 - http://medrxiv.org/content/early/2021/05/15/2021.01.22.21250282.full AB - Reopening schools is an urgent priority as the COVID-19 pandemic drags on. To explore the risks associated with returning to in-person learning and the value of mitigation measures, we developed stochastic, network-based models of SARS-CoV-2 transmission in primary and secondary schools. We find that a number of mitigation measures, alone or in concert, may reduce risk to acceptable levels. Student cohorting, in which students are divided into two separate populations that attend in-person classes on alternating schedules, can reduce both the likelihood and the size of outbreaks. Proactive testing of teachers and staff can help catch introductions early, before they spread widely through the school. In secondary schools, where the students are more susceptible to infection and have different patterns of social interaction, control is more difficult. Especially in these settings, planners should also consider testing students once or twice weekly. Vaccinating teachers and staff protects these individuals and may have a protective effect on students as well. Other mitigations, including mask-wearing, social distancing, and increased ventilation, remain a crucial component of any reopening plan.Competing Interest StatementCTB and RSM consult for Color Health. CTB has received honoraria from Novartis. JRH, HEW and AYZ are currently employed by and have equity interest in Color Health.Funding StatementCTB and RSM were paid consulting fees by Color Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesExtensive documentation and code for the SEIRS+ framework that was developed and used to implement the Extended SEIR Network Model studied in this work can be found at github.com/ryansmcgee/seirsplus. The datasets generated by this work can be explored using an interactive web applet hosted at color.com/impact-of-primary-school-covid-19-testing. Simulation and statistics data will be accessible via the aforementioned github and otherwise made available upon request. https://github.com/ryansmcgee/seirsplus https://www.color.com/impact-of-primary-school-covid-19-testing